Pregled bibliografske jedinice broj: 1125412
Vitamin D in the Patients with Chronic Kidney Disease: When, to Whom and in Which Form
Vitamin D in the Patients with Chronic Kidney Disease: When, to Whom and in Which Form // Mater Sociomed, 27 (2015), 3; 122-124 doi:10.5455/msm.2015.27.122-124 (međunarodna recenzija, pregledni rad, ostalo)
CROSBI ID: 1125412 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Vitamin D in the Patients with Chronic
Kidney Disease: When, to Whom and in
Which Form
Autori
Drasko Pavlovic, Dajana Katicic, Tonko Gulin, Josipa Josipovic
Izvornik
Mater Sociomed (1512-7680) 27
(2015), 3;
122-124
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, ostalo
Ključne riječi
Vitamin D in the Patients with Chronic Kidney Disease: When, to Whom and in Which Form
Sažetak
Alteration in vitamin D metabolism has a central role in the pathogenesis of secondary hyperparathyroidism (SHPT) and is also associated with increased cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). For more than sixty years, vitamin D, nutritional vitamin D (ergocalciferol, cholecalciferol or calcifediol) and nonselective vitamin D receptor (VDR) activators (calcitriol, alfacalcidol) have been used in the prevention and treatment of SHPT. In the last twenty years, selective VDR activators (paricalcitol, maxacalcitol) have been used to target SHPT. However, there are many open questions regarding use of nutritional vitamin D or VDR activators. The K/DOQI and KDIGO guidelines recommended testing for vitamin D insufficiency and deficiency in patients with CKD, but there is no consensus on the definition of vitamin D insufficiency in CKD. There are a many open questions, for example, regarding the optimal nutritional vitamin D type and the dose and co-administration of nutritional vitamin and VDR activators. Therapy with VDRAs is required in the majority of patients with CKD, particularly in dialysis patients. However, when to start with VDRAs is not so apparent. Is PTH level the only indication of when to start therapy? Although VDRAs are very effective in lowering PTH levels and bone metabolism the effect of patients mortality is not so straightforward. Despite many unanswered questions, there is a large body of experimental and clinical data to support vitamin D use in patients with CKD. To obtain answers to the open questions, we need more randomized controlled trials.
Izvorni jezik
Hrvatski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC "Sestre Milosrdnice"